Photo taken from eFFECTOR Therapeutics/LinkedIn
May 22, 2024, 14:42
eFFECTOR Therapeutics announces the initiation of an investigator-sponsored trial in collaboration with the Dana-Farber Cancer Institute
eFFECTOR Therapeutics shared a post on LinkedIn:
“We are excited to announce the initiation of an investigator-sponsored trial evaluating our lead product candidate in patients with estrogen receptor-positive (ER+) endometrial cancer ovarian cancer, in collaboration with the Dana-Farber Cancer Institute. ”
Source: eFFECTOR Therapeutics/LinkedIn